At Some point the FDA must rule on CBD and regulate it for edibles! This my friend will open up the entire market for CPG leaders and CGC is BEST positioned . Bloomberg article- nothing new in it . It touched on the subject about liver issues with CBD use, old news. Nothing confirmed on it, we know that HEAVY daily use in the 100's MG may or may NOT be of concern found in past studies. If you use that much smart people consult with their doctors. Don't believe CONTINENTAL's BS post.
M
Robert it’s not news to anyone that canopy is loosing money even the amount is not a surprise. Every quarter in the report you know what to expect going forward because they tell you! I really don’t understand the complaint? No one forces you to hold. Some people churn to lower there biases . They keep there core holdings and churn trading shares. If you expect profit next quarter there’s no hope for you.
M
Sector is maturing, REVENUE growth in all areas of company. Nice to see a plan in action as we exit the pandemic. CGC BUY STRONG $$$
J
Please call you state senators and representatives and tell them its time to take up cannabis legislation!!!
B
June will prove to be a rebound month for Canopy! Big news on the horizon....
R
I feel so bad for canopy longs and I’m one of them 3 years
J
CGC is supposed to be the best. Here's my issue how can Tlry Stock rise over 4 points in a couple days but Canopy Growth Stock can't move 4 points in months??? The share price of cgc has been stagnant for months. The market imo is becoming a joke when fundamentals don't matter and meme sto ks rise on momentum and wall street hedge funds and analyst play these stocks while good companies with earnings and dividends and value sit stagnant and do nothing. It's becoming a joke.
R
Fox News just said the state of California wants to use tax dollars to save its cannabis industry. This can mean 2 different things. 1. The cannabis industry is a much smaller market then they thought and most people still getting from black market. 2. This shows that Democrats officials in California don’t know how to lead anything
j
If the sector was so bullish , STZ would exercise their warrants and increase position.
d
Happy Friday! Both cgc and acrhf up a penny! Got love the weekend…ha Fingers crossed…better days!
j
Background: I’ve been an investor well before CND legalization. Here’s the problem with the sector… We are relying on the demos to actually do something reasonable and at a reasonable rate.
Canopy was built for growth (do you think Const. would put 3- 4 Billion for Canada market?) -Their zealous Canadian plans was wasteful. -Their over seas expansion has proved a waste. If USA doesn’t FULLY legalize this year, investors will feel the $150 mil quarter pinch over and over. We MIGHT get the SAFE act or MORE act but doubtfully full legalization from the hop. Bottom line: Don’t trust lifelong politicians like Schumer. Demos were playing the senate card for 4 years. Now what?
B
did the PLO snipe Sansu?
J
Analyst: Canopy's Earnings Reveal Stable B2B And Impressive CBD Sales; It's Still The Leader Of The Group Canopy Growth Corporation (TSX: WEED, NASDAQ: CGC) Benzinga · 6/2/2021, 10:33:56 AM Disclaimer: This article represents only the author's personal opinion and does not constitute ... Unfold Listen to the news Canopy Growth Corporation (TSX: WEED, NASDAQ: CGC) disclosed Tuesday its fourth-quarter and fiscal year 2021 financial results with a net loss for the year of CA$1.7 billion ($1.41 billion), representing a CA$283 million wider loss as compared to FY 2020.
The Canadian cannabis giant also reported a quarterly net loss of CA$617 million, representing a CA$710 million narrower loss compared to the same quarter of fiscal 2020. Both adjusted EBITDA figures were negative amounting to a loss of CA$340 million for the year, and a loss of CA$94 million for the quarter.
The Analyst Cantor Fitzgerald’s analyst Pablo Zuanic kept a ‘Neutral’ rating on Canopy’s stock, lowering their price target to CA$30.50 from C$32.
The Investment Thesis Canopy’s quarterly business-to-business sales were stable, and therefore better than its competition and previously provided outlook, explained Zuanic in a Tuesday note.
According to the analyst, good business-to-business sales in the quarter should reveal significantly advanced March shipments, with many other cannabis companies reporting double-digit drops in adult-use shipments for the same period. “So, in that context, these are good numbers.”
With CBD sales near CA$7 million, or a fourth of the size of Charlotte’s Web (OTCQX: CWBHF), Canopy made terrific results in a short period, noted Zuanic.
“Overall, we would call this a pretty decent top-line quarter given the industry context. Profit metrics worsened sequentially, but guidance for breakeven EBITDA by end of the fiscal year 2022 was kept.”
The analyst further noted that even though they remain ‘Neutral’ on the stock, they recognize that Canopy is the leader among other Canadian cannabis companies, “and with the sector outlook improving, we would expect the stock to move up today.”
C
CANOPY Growth and Biosteel. Potential problem for the CBD markets
Not selling until 100bn mc. $tlry $cgc $curlf my only long term holds
R
☆ CGC ☆ Brightest Star in sector
☆ CGC STRONG LONG $$$
p
Decent volume today. Good luck to all.
A
Not trying to bash Tilray (I actually hold TLRY as well) but they are not even close to comparable to CGC. Not only is CGC already selling lots of product in the US, but they have massive brick and mortar presence in Canada which gives them a massive advantage. TLRY is relying on the retail out their to chose their product for their shelf space where as Canopy has probably close to 80-100 stores across the country to push their own products in addition to the other retail players selling their products.
Notice how last quarter Canopy actually achieved sales growth even though it was a extremely tough quarter for the industry, While TLRY and APHA suffered shrinking sales? IMO, this is directly tied to the fact CGC has retail while TLRY doesn’t.
J
Cannabis-Focused RIV Capital Reports Q4 And Fiscal Year 2021 Results, Closes Deal With Canopy Growth Cannabis-focused investment and acquisition company, RIV Capital Inc. (TSX: RIV) (OTCQX: CNPOF) posted its latest financial earnings report on Thursday, touting a pop in total comprehensive income that hit CA$64.8 million ($53.7 million) in the fourth qua... Benzinga · 6/3/2021, 12:32:13 PM Disclaimer: This article represents only the author's personal opinion and does not constitute ... Unfold Listen to the news Cannabis-focused investment and acquisition company, RIV Capital Inc.
(TSX:RIV) (OTCQX: CNPOF) posted its latest financial earnings report on Thursday, touting a pop in total comprehensive income that hit CA$64.8 million ($53.7 million) in the fourth quarter of 2021.
With a portfolio of 12 cannabis companies, the Toronto-based company reported a strong balance sheet, with roughly CA$335.4 million in total assets.
In February, RIV Capital closed its previously announced deal with Canopy Growth Corporation (TSX:WEED) (NASDAQ:CGC) to dispose of certain financial assets it held in TerrAscend Corp.(CSE:TER) (OTCQX:TRSSF), TerrAscend Canada Inc., The Tweed Tree Lot Inc., and Les Serres Vert Cannabis Inc.
In return, the company received $118.4 million in cash, roughly 3.65 million common shares of Canopy Growth and the cancellation of multiple voting shares and subordinated voting shares of the company that Canopy Growth held.
"This transaction returned several multiples on invested capital and provided us with the strategic flexibility needed to pivot our business model," Narbé Alexandrian, president and CEO of RIV Capital, said.
In March, the company's 49%-owned joint venture in Ontario - PharmHouse Inc. - opted to sell its greenhouse facility alongside certain equipment. Once the Ontario Superior Court of Justice approved the PharmHouse Sale, RIV Capital paid $25 million to the lender of PharmHouse's $90.0 million non-revolving syndicated credit facility. Following the closing of the PharmHouse sale, the company paid an additional $7.5 million to the lenders to satisfy its obligations under the PharmHouse credit facility.
"With the CGC Transaction complete and the PharmHouse Credit Facility fully settled, our rejuvenated balance sheet puts us in an advantageous position to capitalize on the growing momentum in the U.S. cannabis market," Eddie Lucarelli, CFO of RIV Capital, disclosed.
R
Really wishing I sold all my shares at 45 instead of selling just a 1/4 of my shares
Don't believe CONTINENTAL's BS post.
CGC BUY STRONG $$$
Fingers crossed…better days!
Here’s the problem with the sector…
We are relying on the demos to actually do something reasonable and at a reasonable rate.
Canopy was built for growth (do you think Const. would put 3- 4 Billion for Canada market?)
-Their zealous Canadian plans was wasteful.
-Their over seas expansion has proved a waste.
If USA doesn’t FULLY legalize this year, investors will feel the $150 mil quarter pinch over and over.
We MIGHT get the SAFE act or MORE act but doubtfully full legalization from the hop.
Bottom line: Don’t trust lifelong politicians like Schumer. Demos were playing the senate card for 4 years. Now what?
Canopy Growth Corporation (TSX: WEED, NASDAQ: CGC)
Benzinga
·
6/2/2021, 10:33:56 AM
Disclaimer: This article represents only the author's personal opinion and does not constitute ... Unfold
Listen to the news
Canopy Growth Corporation (TSX: WEED, NASDAQ: CGC) disclosed Tuesday its fourth-quarter and fiscal year 2021 financial results with a net loss for the year of CA$1.7 billion ($1.41 billion), representing a CA$283 million wider loss as compared to FY 2020.
The Canadian cannabis giant also reported a quarterly net loss of CA$617 million, representing a CA$710 million narrower loss compared to the same quarter of fiscal 2020. Both adjusted EBITDA figures were negative amounting to a loss of CA$340 million for the year, and a loss of CA$94 million for the quarter.
The Analyst
Cantor Fitzgerald’s analyst Pablo Zuanic kept a ‘Neutral’ rating on Canopy’s stock, lowering their price target to CA$30.50 from C$32.
The Investment Thesis
Canopy’s quarterly business-to-business sales were stable, and therefore better than its competition and previously provided outlook, explained Zuanic in a Tuesday note.
According to the analyst, good business-to-business sales in the quarter should reveal significantly advanced March shipments, with many other cannabis companies reporting double-digit drops in adult-use shipments for the same period. “So, in that context, these are good numbers.”
With CBD sales near CA$7 million, or a fourth of the size of Charlotte’s Web (OTCQX: CWBHF), Canopy made terrific results in a short period, noted Zuanic.
“Overall, we would call this a pretty decent top-line quarter given the industry context. Profit metrics worsened sequentially, but guidance for breakeven EBITDA by end of the fiscal year 2022 was kept.”
The analyst further noted that even though they remain ‘Neutral’ on the stock, they recognize that Canopy is the leader among other Canadian cannabis companies, “and with the sector outlook improving, we would expect the stock to move up today.”
https://www.bloomberg.com/news/articles/2021-06-14/pro-athletes-cbd-use-coming-under-scrutiny-cannabis-weekly?srnd=technology-vp&sref=rUD130XG
☆ CGC STRONG LONG $$$
Notice how last quarter Canopy actually achieved sales growth even though it was a extremely tough quarter for the industry, While TLRY and APHA suffered shrinking sales? IMO, this is directly tied to the fact CGC has retail while TLRY doesn’t.
Cannabis-focused investment and acquisition company, RIV Capital Inc. (TSX: RIV) (OTCQX: CNPOF) posted its latest financial earnings report on Thursday, touting a pop in total comprehensive income that hit CA$64.8 million ($53.7 million) in the fourth qua...
Benzinga
·
6/3/2021, 12:32:13 PM
Disclaimer: This article represents only the author's personal opinion and does not constitute ... Unfold
Listen to the news
Cannabis-focused investment and acquisition company, RIV Capital Inc.
(TSX:RIV) (OTCQX: CNPOF) posted its latest financial earnings report on Thursday, touting a pop in total comprehensive income that hit CA$64.8 million ($53.7 million) in the fourth quarter of 2021.
With a portfolio of 12 cannabis companies, the Toronto-based company reported a strong balance sheet, with roughly CA$335.4 million in total assets.
In February, RIV Capital closed its previously announced deal with Canopy Growth Corporation (TSX:WEED) (NASDAQ:CGC) to dispose of certain financial assets it held in TerrAscend Corp.(CSE:TER) (OTCQX:TRSSF), TerrAscend Canada Inc., The Tweed Tree Lot Inc., and Les Serres Vert Cannabis Inc.
In return, the company received $118.4 million in cash, roughly 3.65 million common shares of Canopy Growth and the cancellation of multiple voting shares and subordinated voting shares of the company that Canopy Growth held.
"This transaction returned several multiples on invested capital and provided us with the strategic flexibility needed to pivot our business model," Narbé Alexandrian, president and CEO of RIV Capital, said.
In March, the company's 49%-owned joint venture in Ontario - PharmHouse Inc. - opted to sell its greenhouse facility alongside certain equipment. Once the Ontario Superior Court of Justice approved the PharmHouse Sale, RIV Capital paid $25 million to the lender of PharmHouse's $90.0 million non-revolving syndicated credit facility. Following the closing of the PharmHouse sale, the company paid an additional $7.5 million to the lenders to satisfy its obligations under the PharmHouse credit facility.
"With the CGC Transaction complete and the PharmHouse Credit Facility fully settled, our rejuvenated balance sheet puts us in an advantageous position to capitalize on the growing momentum in the U.S. cannabis market," Eddie Lucarelli, CFO of RIV Capital, disclosed.